While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

Arcus Biosciences (RCUS) announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences (GILD) ...

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in ...

Merck’s Keytruda, the category-defining CPI, reported $29.5 billion in revenue in 2024, with NSCLC representing an estimated 30% of its total sales. Keytruda is expected to approach $35 billion by ...

Marianne D'Amico-Ferrari has spent 29 years teaching in Trumbull. Families know her as steady and kind. Students describe her ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer ...